



Curriculum vitae
Europass

Informații personale

Nume / Prenume Zdrenghea, Mihnea Tudor
Telefon(oane)
E-mail(uri) mzdrenghea@umfcluj.ro
Brainmap code:U-1700-029Q-9646

Data nașterii 22 ianuarie 1973

Locul de muncă vizat /
Domeniul ocupațional Profesor Universitar Disciplina Hematologie, Departamentul Oncologie

Experiența profesională

2016-prezent Conferențiar Universitar, disciplina Hematologie, UMF Cluj
2012-prezent Șef de lucrări, catedra Hematologie, UMF Cluj
2005-prezent Medic hematolog, IOCN
2004-2012 Asistent, catedra Hematologie, UMF Cluj
2001-2002 Intern în Hematologie, Hopital de Hautepierre, Strasbourg
1999-2004 Rezident de hematologie, Spitalul Județean Oradea și IOCN

Educație și formare

2015 Abilitare, UMF Cluj-Napoca
2009 Diploma de Doctorat, UMF Cluj-Napoca
2009 Medic Primar hematologie
2005-2006 European Respiratory Society Fellow, Imperial College London
2004 Specialist în hematologie
2003 Academic visitor, UCB scholarship award, Imperial College London
2001-2002 Attestation Formation Spécialisée en Hematologie, Université Louis Pasteur, Strasbourg, France
1997 Licența în Medicină, UMF Cluj-Napoca

Alte activitati

Din 2020 Membru CNATDCU, Comisia de Medicina
Din 2017 Membru in Comisia de Specialitate Hematologie a MS

2015-ian 2017 Presedinte al Comisiei de Specialitate Hematologie a MS

Limba(i) maternă(e) Romana

Limba(i) străină(e) cunoscută(e)

Autoevaluare

Nivel european (*)

Limba Franceza Medicala (B2)

Limba Engleza (Cambridge
ESOL, C2)

Înțelegere		Vorbire		Scriere
Ascultare	Citire	Participare la conversație	Discurs oral	Exprimare scrisă
204	201	204	208	190

(*) Nivelul Cadrului European Comun de Referință Pentru Limbi Străine

Premii si distinctii

Premiul "Octavian Fodor", UMF Cluj, 2012
Premiul Pentru Tineri Cercetatori, UMF Cluj, 2012

Competențe și aptitudini
organizatorice

Organizator al 5 Workshopuri cu participare internationala


Competențe și aptitudini tehnice Cunostinte avansate de munca de laborator de cercetare (culturi celulare, PCR,
etc.

Scientometrie

Indice Hirsch (Web of Science): 13. Peste 70 de lucrari publicate, in reviste
indexate WOS. Peste 80 de lucrari indexate Pubmed.

Membru in Societati
Profesionale

Societatea Romana de Hematologie, Asociatia Europeana de Hematologie,
European Research Initiative on Chronic Lymphocytoc Leukemia (ERIC)



Granturi de cercetare

Director de proiect:

UMF Grant intern competitia 2013
UMF Grant intern 27020/17 -2011
UEFISCDI PNII – IDEI/ WE-4-084/ 2012
UEFISCDI PN-II-RU-PD-2011-3-0277


Membru in echipa :

UEFISCDI PNII – ID-PCE-2012-4-0417

Altele:

ERS long term research fellowship, Imperial College London, 2005-6
UCB short term travel award, Imperial College London, 2003
The Wellcome Trust Visitor Fellowship, Imperial College London, 2001
Beneficiar grant POSDRU

Cluj Napoca
1 iulie 2021

A handwritten signature in black ink, consisting of several overlapping strokes that form a stylized, somewhat abstract shape.

Lista de articole științifice

1. Articole publicate in extenso în reviste și volumele unor manifestări științifice indexate ISI, Web of Science, Core collection.


Autor principal

Nr. Crt.	Titlul	Autorii	Calitatea autorului ¹	Revista, volum, nr. pagini	Factorul de impact ²	Quartila	Anul ³
1	N-terminal pro-B type natriuretic peptide during exercise in patients with systolic and diastolic heart failure	Zdrenghea D, Ilea N, Pop D, Petrovai D, Bodisz G, Zdrenghea M.	Ultim autor	Acta Endocrinologica – Bucharest. 5(1): 6 pg	IF=0.011	Q4	2009
2	RSV infection modulates IL-15 production and MICA levels in respiratory epithelial cells.	Zdrenghea MT, Telcian AG, Laza-Stanca V, Bellettato CM, Edwards MR, Nikonova A, Khaitov MR, Azimi N, Groh V, Mallia P, Johnston SL, Stanciu LA.	Prim autor	Eur Respir J. 39(3):712-20. doi: 10.1183/09031936.00099811. 9 pg.	IF=7.12	Q1	2012
3	Role of PD-L1/PD-1 in the immune response to respiratory viral infections.	Zdrenghea MT, Johnston SL.	Prim autor	Microbes Infect. 14(6):495-9. doi: 10.1016/j.micinf.2012.01.002. 5 pg.	IF=2.73.	Q2	2012
4	Immunological pathways in virus-induced COPD exacerbations: a role for IL-15.	Zdrenghea MT, Mallia P, Johnston SL.	Prim autor	Eur J Clin Invest. 42(9):1010-5. doi: 10.1111/j.1365-2362.2012.02672.x. 6 pg.	IF=2.83.	Q1	2012
5	Could interleukin-15 potentiate histone deacetylase inhibitor effects in haematological malignancy?	Zdrenghea MT.	Autor unic	Med Hypotheses. 81(2):311-5. doi: 10.1016/j.mehy.2013.04.021 5 pg.	IF=1.15.	Q4	2013
6	Dissociated evolution of a multifocal primary CNS	Bagacean C, Zdrenghea M,	Autor corespondent	J BUON.; 18(4):1098. 1 pag.	IF= 0,706	Q4	2013



	lymphoma.	Popescu C, Quintin-Roue I, Ianotto JC, Eveillard JR, Berthou C, Tempescul A.						
7	Evolution of cardiovascular risk factors and ischemic heart disease in an elderly urban Romanian population over the course of 1 year.	Pop D, Dadarlat A, Zdrenghea M , Zdrenghea DT, Sitar-Taut AV.	Autor corespondent	Clin Interv Aging; 8:1497-503 6 pg	IF=1,82	Q3	2013	
8	The Effect of Maximal and Submaximal Exercise Testing on NT-proBNP Levels in Patients with Systolic Heart Failure	Zdrenghea DT, Ilea M, Zdrenghea M , Sitar-Taut AV, Pop D.	Autor corespondent	Revista Romana de Medicina de Laborator; 22(1):25-33. 8 pg	IF=0,239	Q4	2014	
9	Soluble major histocompatibility complex class I-related chain B molecules are increased and correlate with clinical outcomes during rhinovirus infection in healthy subjects.	Telcian AG, Zdrenghea MT , Caramori G, Laza-Stanca V, Message SD, Kebabze T, et al.	Autor corespondent	Chest. 146(1):32-40. 8 pg	IF=7,13	Q1	2014	
10	NT-pro-BNP during isotonic and isometric exercise in heart failure patients with preserved LV ejection fraction.	Zdrenghea DT, Ilea M, Bodizs G, Sitar-Taut A, Zdrenghea M , Pop D.	Autor corespondent	Clin Lab. 60(12):2055-61 6 pg	IF= 1,129	Q4	2014	
11	The role of macrophage IL-10/innate IFN interplay during virus-induced asthma.	Zdrenghea MT , Makrinitoti H, Muresan A, Johnston SL, Stanciu LA.	Prim autor	Rev Med Virol. 25(1):33-49. 13 pg	IF=5,75	Q1	2015	
12	Ofatumumab in a chronic lymphocytic leukemia patient with graft versus host disease and relapse after mini-alloBMT.	Urian L, Renaudineau Y, Berthou C, Zdrenghea M , Petrov L, Tempescul A.	Autor corespondent	J BUON. 20(2):668-9. 2 pg	IF= 0,880	Q4	2015	
13	Exudative pericarditis in the evolution of a diffuse large B-	Bagacean C, Tempescul A, Ianotto	Ultim autor	Cardiovasc J Afr. 26(4):e9-e11 3 pg	IF=1,022	Q4	2015	

14	ESHAP chemotherapy is efficient in refractory/relapsed primary central nervous system lymphoma: report of four cases	JC, Marion V, Pop D, Zdrenghea M. Ungur R, Tempescul A, Berthou C, Bagacean C, Radeanu D, Muresan A, Zdrenghea M.	Ultim autor	Onco Targets Ther.;8:2771-3. 3 pg	IF=2.31	Q2	2015
15	Cardiopulmonary exercise testing in improving the rehabilitation of patients with heart failure and anemia.	Guşetu G, Zdrenghea M, Pop D, Popescu C, Muresan A.	Autor correspondent	Balneo Research Journal.; 6(2): 195-198. 4 pg	IF=0		2015
16	Late relapsing mantle cell lymphoma showing preserved sensitivity to single-agent lenalidomide.	Tempescul, A; Ianoţto, JC; Bagacean, C; Salaun, PY; Bocsan, C; Zdrenghea, M.	Ultim autor	INTERNATIONAL JOURNAL OF HEMATOLOGY;1043:400-402 .doi:10.1007/s12185-016-2020-4 3 pg	IF=1.61	Q4	2016
17	Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro.	Telcian, AG; Zdrenghea, MT; Edwards, MR; Lazastanca, V; Mallia, P; Johnston, SL; Stanciu, LA.	Autor correspondent	ANTIVIRAL RESEARCH;137:93-101 .doi:10.1016/j.antiviral.2016.11.004 8 pg	IF=4.3	Q1	2017
18	Atypical aleukemic presentation of large granular lymphocytic leukemia: a case report.	Bagacean, C; Tempescul, A; Patiu, M; Fetica, B; Bumbea, H; Zdrenghea, M.	Ultim autor	ONCOTARGETS AND THERAPY;10:31-34 .doi:10.2147/OTT.S115892 4 pg	IF=2.65	Q3	2017
19	The use of rotation to fentanyl in cancer-related pain.	Dima, D; Tomuleasa, C; Frinc, I; Pasca, S; Magdo, L; Berindan-Neagoe, I; Muresan, M; Lisencu, C; Irimie, A; Zdrenghea, M.	Ultim autor	JOURNAL OF PAIN RESEARCH;10:341-348 .doi:10.2147/JPR.S121920 7 pg	IF=2.64	Q3	2017
20	Vitamin D modulation of innate immune responses to respiratory viral infections.	Zdrenghea, MT; Makrinoti, H; Bagacean, C; Bush, A; Johnston, SL; Stanciu, LA.	Prim autor	REVIEWS IN MEDICAL VIROLOGY;271:e1909.doi:10.1002/rmv.1909	IF=5.034	Q1	2017



21	Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.	Ilcus, C; Bagacean, C; Tempescu, A; Popescu, C; Parvu, A; Cenariu, M; Bocsan, C; Zdrenghea, M.	Ultim autor	ONCOTARGETS AND THERAPY;10:2349-2363 .doi:10.2147/OTT.S133385 14 pg	IF=2.65	Q3	2017
22	Xanthine oxidase inhibitors in ischaemic heart disease.	Zdrenghea, M; Sitar-Taut, A; Cismaru, G; Zdrenghea, D; Pop, D	Prim autor	CARDIOVASCULAR JOURNAL OF AFRICA;283:201-204 .doi:10.5830/CVJA-2016-068 4 pg	IF=1.12	Q4	2017
23	NT-PRO-BNP AND URIC ACID LEVELS CORRELATE IN PATIENTS WITH COPD AND HEART FAILURE.	Iosip, A; Pop, D; Sitar-Taut, A; Niculescu, I; Caloian, B; Zdrenghea, D; Zdrenghea M	Ultim autor	ACTA MEDICA MEDITERRANEA;341:189-195 .doi:10.19193/0393-6384_2018_1_31 6 pg	IF=0.35	Q3	2018
24	Preserved lenalidomide efficacy in a recurrent isolated subcutaneous mantle cell lymphoma relapse.	Bagacean C, Neaga A, Zdrenghea M, Tempescu A.	Autor corespondent	J BUON.;23(1):273-274. 2 pg	IF=1.379	Q4	2018
25	A Review of Macrophage MicroRNAs' Role in Human Asthma.	Feketea G, Bocsan CI, Popescu C, Gaman M, Stanciu LA, Zdrenghea MT.	Ultim autor	Cells.;8(5):420. doi: 10.3390/cells8050420 21 pg	IF=4.366	Q2	2019
26	Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients?	Popescu CM, Ursache AL, Feketea G, Bocsan C, Jimbu L, Mesaros O, Edwards M, Wang H, Berceanu I, Neaga A, Zdrenghea M.	Ultim autor	Microorganisms.;7(1):521. doi: 10.3390/microorganisms7110521. 23 pg	IF=4.128	Q2	2019
27	The Role of Vitamin D Deficiency in Children With Recurrent Wheezing-Clinical Significance.	Feketea G, Bocsan CI, Stanciu LA, Buzoianu AD, Zdrenghea MT.	Ultim autor	Front Pediatr.;8:344. doi: 10.3389/fped.2020.00344. eCollection 2020 7 pg	IF=3.418	Q1	2020



28	Macrophage Polarization in Chronic Lymphocytic Leukemia: Nurse-Like Cells Are the Caretakers of Leukemic Cells.	Mesaros O, Jimbu L, Neaga A, Popescu C, Berceanu I, Tomuleasa C, Fetica B, Zdrenghea M.	Ultim autor	Biomedicines.8(11):516. doi: 10.3390/biomedicines8110516 17 pg	IF=6.081	Q1	2020
29	TET2/IDH1/2/WT1 and NPM1 Mutations Influence the RUNX1 Expression Correlations in Acute Myeloid Leukemia.	Pasca, S; Jurj, A; Tomuleasa, C; Zdrenghea, M.	Ultim autor	MEDICINA-LITHUANIA 5; 612:-637. doi:10.3390/medicina56120637	IF=2.43	Q2	2020
30	MicroRNAs Associated With a Good Prognosis of Acute Myeloid Leukemia and Their Effect on Macrophage Polarization.	Neaga A, Bagacean C, Tempescul A, Jimbu L, Mesaros O, Blag C, Tomuleasa C, Bocsan C, Gaman M, Zdrenghea M.	Ultim autor	Front Immunol. 11:582915. doi: 10.3389/fimmu.2020.582915 14 pg	IF=5.085	Q1	2021
31	Vitamin D Status in Children in Greece and Its Relationship with Sunscreen Application.	Feketea GM, Bocsan IC, Tsiros G, Voila P, Stanciu LA, Zdrenghea M.	Ultim autor	Children (Basel). 8(2):111. doi: 10.3390/children8020111. 11 pg	IF=2.078	Q2	2021
32	Vitamin D in Corona Virus Disease 2019 (COVID-19) Related Multisystem Inflammatory Syndrome in Children (MIS-C).	Feketea G, Vlacha V, Bocsan IC, Vassilopoulou E, Stanciu LA, Zdrenghea M.	Ultim autor	Front Immunol. 12:648546. doi:10.3389/fimmu.2021.648546 7 pg	IF=5.085	Q1	2021
33	Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?	Jimbu L, Mesaros O, Popescu C, Neaga A, Berceanu I, Dima D, Gaman M, Zdrenghea M.	Ultim autor	Pharmaceuticals (Basel). 14(4):288. doi:10.3390/ph14040288 18 pg	IF=4.286	Q1	2021

¹ se va nota (prim autor, autor corespondent, ultim autor, autor cu contributii egale)


² se va nota factorul de impact in anul aparitiei articolului

Coautor

Nr. Crt.	Titlul	Autorii	Revista, volum, nr. pagini	Factorul de impact ²	Quartila	Anul ³
1	RSV-induced bronchial epithelial cell PD-L1 expression inhibits CD8+ T cell nonspecific antiviral activity.	Telcian AG, Laza-Stanca V, Edwards MR, Harker JA, Wang H, Bartlett NW, Mallia P, Zdrenghea MT , Kebabdzic T, Coyle AJ, Openshaw PJ, Stanciu LA, Johnston SL.	J Infect Dis. 203(1):85-94. doi: 10.1093/infdis/jtq020. 10 pg	IF=5.77	Q1	2011
2	The role of IL-15 deficiency in the pathogenesis of virus-induced asthma exacerbations.	Laza-Stanca V, Message SD, Edwards MR, Parker HL, Zdrenghea MT , Kebabdzic T, Kon OM, Mallia P, Stanciu LA, Johnston SL.	PLoS Pathog. 7(7):e1002114. doi: 10.1371/journal.ppat.1002114.	IF= 8.05	Q1	2011
3	A cerebral hemorrhagic complication following PBSC collection.	Adrian T, Mihnea Zdrenghea , Francoise Q, Jean-Richard E, Christian B, Jean-Christophe I.	Ann Hematol. 90(2):221-2. 2 pg	IF=2.615	Q2	2011
4	Systemic sclerosis-polymyositis overlap syndrome associated with autoimmune hepatitis and cerebral vasculitis	Pamfil C, Zdrenghea MT , Mircea PA, Manzat Saplacan RM, Rednic N, Rednic S.	J Gastrointestin Liver Dis. 21(3):317-20 4 pg	IF=1.855	Q3	2012
5	Ultrasonography of the spleen.	Chiorean L, Zdrenghea M , Badea R.	Pictorial essay. Med Ultrason. 16(1):48-59. 12 pg	IF= 1.1	Q4	2014
6	Cardiopulmonary exercise testing in improving the rehabilitation of patients with heart failure and	Gusetu, G; Zdrenghea, M ; Dana, P; Popescu, C; Adina, M.	BALNEO RESEARCH JOURNAL;63:195-198 .doi:10.12680/balneo.2015.1105 4 pg	IF=0		2015

7	anemia.	Gold nanoparticles enhance the effect of tyrosine kinase inhibitors in acute myeloid leukemia therapy.	Petrushev, B; Boca, S; Simon, T; Berce, C; Frinc, I; Dima, D; Selicean, S; Gafencu, GA; Tanase, A; Zdrenghia, M ; Florea, A; Suarasan, S; Dima, L; Stanciu, R; Jurj, A; Buzoianu, A; Cucuianu, A; Astilean, S; Irimie, A; Tomuleasa, C; Berindan-Neagoe, I.	INTERNATIONAL JOURNAL OF NANOMEDICINE:11:641-660 .doi:10.2147/IJN.S94064 20 pg	IF=4.3	Q2	2016
8		Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises.	Bagacean, C; Zdrenghia, M ; Tempescul, A; Cristea, V; Renaudineau, Y.	IMMUNOTHERAPY:85:569-581 .doi:10.2217/imt-2015-0015 12 pg	IF=2.716	Q3	2016
9		TERT rs2736100 A > C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.	Trifa, AP; Banescu, C; Tevet, M; Bojan, A; Dima, D; Urian, L; Torok-Vistai, T; Popov, VM; Zdrenghia, M ; Petrov, L; Vasilache, A; Murat, M; Georgescu, D; Popescu, M; Patrinoiu, O; Balea, M; Costache, R; Coles, E; Saguna, C; Berbec, N; Vladareanu, AM; Mihaila, RG; Bumbea, H; Cucuianu, A; Popp, R.A.	BRITISH JOURNAL OF HAEMATOLOGY:1742:218-226 .doi:10.1111/bjh.14041 9 pg	IF=5.670	Q1	2016
10		Chondroprotective effects of pulsed shortwave therapy in rabbits with experimental osteoarthritis.	Ungur, RA; Florea, A; Tabaran, AF; Scurtu, IC; Onac, I; Borda, IM; Irsay, L; Ciortea, VM; Dronca, E; Zdrenghia, MT ; Suci, SM.	JOURNAL OF MORPHOLOGY AND EMBRYOLOGY:582:465-472 7 pg	IF=0.912	Q4	2017


7



	ROMANIAN						
11	Combining cytogenetic and epigenetic approaches in chronic lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion.	Bagacean C, Le Dantec C, Berthou C, Tempescul A, Saad H, Bordron A, Zdrenghea M, Cristea V, Douet-Guilbert N, Renaudineau Y.	Clin Epigenetics.;9:122. doi: 10.1186/s13148-017-0422-7.	IF=6.091			2017
12	Echocardiography as the first diagnostic clue to rapidly progressive systemic AL amyloidosis associated with multiple site thrombosis. A case report.	Caloian B, Zdrenghea D, Man SC, Costea S, Zdrenghea M, Pop D.	Med Ultrason.;19(4):451-453. doi: 10.11152/mtu-1095. 3 pg	IF=1.512	Q3		2017
13	Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 BCR-ABL transcripts.	Dima D, Oprita L, Rosu AM, Trifa A, Selicean C, Moisoiu V, Frinc I, Zdrenghea M, Tomuleasa C.	Onco Targets Ther. 10:5047-5051. doi: 10.2147/OTT.S146973. 5 pg	IF=2.65	Q3		2017
14	Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycythemia vera and essential thrombocythemia.	Trifa AP, Bănescu C, Voina CM, Popa Ș, Török-Vistai T, Bojan AS, Dima D, Zdrenghea M, Fetica B, Vișan S, Tomuleasa C, Pârvu A, Urian L, Pop B, Popov VM, Andreescu M, Popp RA.	BLOOD CELLS MOLECULES AND DISEASES. 73: 45-46 2 pg	IF=2.305	Q3		2018
15	Exosome-carried microRNA-based	Jurj A, Pop L, Petrushev B, Pasca S, Dima D, Frinc I, Deak D,	Crit Rev Clin Lab Sci. ;55(7):501-515. doi: 10.1080/10408363.2018.1499707	IF=4.817	Q1		2018

	signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome.	Desmirean M, Trifa A, Fetica B, Gafencu G, Selicean S, Moisoiu V, Micu WT, Berce C, Sacu A, Moldovan A, Colita A, Bumbea H, Tanase A, Dascalescu A, Zdrenghia M , Stiufiuc R, Leopold N, Tetean R, Burzo E, Tomuleasa C, Berindan-Neagoe I.	15 pg			
16	Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently available laboratory approaches.	Tomuleasa C, Selicean C, Cismas S, Jurj A, Marian M, Dima D, Pasca S, Petrushev B, Moisoiu V, Micu WT, Vischer A, Arifeen K, Selicean S, Zdrenghia M , Bumbea H, Tanase A, Grewal R, Pop L, Aanei C, Berindan-Neagoe I.	Crit Rev Clin Lab Sci. 55(5):329-345. doi: 10.1080/10408363.2018.1463508. Epub 2018 May 25.	IF=4.817	Q1	2018
17	Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis.	Tomuleasa, C; Selicean, S; Gafencu, G; Petrushev, B; Pop, L; Berce, C; Jurj, A; Trifa, A; Rosu, AM; Pasca, S; Magdo, L; Zdrenghia, M ; Dima, D; Tanase, A; Frinc, I; Bojan, A; Berindan-Neagoe, I; Ghiaur, G; Ciurea, SO.	JOURNAL OF CELLULAR PHYSIOLOGY;2331:422-433 .doi:10.1002/jcp.25902 12 pg	IF=4.522	Q2	2018
18	Rapid and complete response to idelalisib in a case of Richter syndrome.	Bagacean C, Zdrenghia M , Saad H, Berthou C, Renaudineau Y, Tempescul A.	Onco Targets Ther.12:1181-1184. doi: 10.2147/OTT.S187459 4 pg	IF=3.046	Q2	2019
19	17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.	Bagacean C, Tempescul A, Ternant D, Banet A, Douet-Guilbert N, Bordron A, Bendaoud B, Saad H, Zdrenghia M , Berthou C, Paintaud G, Renaudineau Y.	J Immunother Cancer.;7(1):22. doi: 10.1186/s40425-019-0509-0.	IF=10.252	Q1	2019


20	Approach to the Adult Acute Lymphoblastic Leukemia Patient.	Sas V, Moisiu V, Teodorescu P, Tranca S, Pop L, Iluta S, Pasca S, Blag C, Man S, Roman A, Constantinescu C, Rus I, Buse M, Fetica B, Marian M, Selicean C, Berindan-Neagoe I, Petrushev B, Bumbea H, Tanase A, Zdrenghea M, Fuji S, Kitano S, Tomuleasa C; Romanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation.	J Clin Med.;8(8):1175. doi: 10.3390/jcm8081175.	IF=3.303	Q1	2019
21	Transient leukemia of Down syndrome.	Sas V, Blag C, Zaharie G, Puscas E, Lisencu C, Andronic-Gorcea N, Pasca S, Petrushev B, Chis I, Marian M, Dima D, Teodorescu P, Iluta S, Zdrenghea M , Berindan-Neagoe I, Popa G, Man S, Colita A, Stefan C, Kojima S, Tomuleasa C.	Crit Rev Clin Lab Sci.;56(4):247-259. doi:10.1080/10408363.2019.1613629. 13 pg	IF=4.677	Q1	2019
22	Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology.	Moisiu V, Teodorescu P, Parajdi L, Pasca S, Zdrenghea M , Dima D, Precup R, Tomuleasa C, Soverini S.	Front Oncol. 9:863. doi: 10.3389/fonc.2019.00863. 8 pg	IF=4.848	Q2	2019
23	Persistent Basophilia May Suggest an "Accelerated Phase" in the Evolution of CALR-Positive Primary Myelofibrosis Toward Acute Myeloid Leukemia.	Dobrowolski J, Pasca S, Teodorescu P, Selicean C, Rus I, Zdrenghea M , Bojan A, Trifa A, Fetica B, Petrushev B, Rosu AM, Berindan-Neagoe I, Tomuleasa C, Dima D.	Front Oncol. 9:872. doi: 10.3389/fonc.2019.00872. 7 pg	IF=4.848	Q2	2019



24	CV RISK - A new relative cardiovascular risk score.	Zdrengheta D, Gușetu G, Zdrengheta M , Cismaru G, Caloian B, Vaidean G, Pop D.	Med Hypotheses. 132:109362. doi: 10.1016/j.mehy.2019.109362. 4 pg	IF=1.378	Q4	2019
25	Let's Talk About BiTEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia.	Deak D, Pop C, Zimta AA, Jurj A, Ghiaur A, Pasca S, Teodorescu P, Dascalescu A, Antohe I, Ionescu B, Constantinescu C, Onaciu A, Munteanu R, Berindan-Neagoe I, Petrushev B, Turcas C, Iluta S, Selicean C, Zdrengheta M , Tanase A, Danaïla C, Colita A, Colita A, Dima D, Coriu D, Einsele H, Tomuleasa C.	Front Immunol.10:2856. doi: 10.3389/fimmu.2019.02856. 16 pg	IF=7.561	Q1	2019
26	Splenectomy in Lymphoproliferative Disorders: A Single Eastern European Center Experience.	Onisăi M, Vlădăreanu AM, Nica A, Spînu A, Găman M, Bumbea H, Voican I, Iordan I, Alexandru A, Zdrengheta M , Gheorghita D, Grădinaru S.	Medicina (Kaunas). 56(1):12. doi: 10.3390/medicina56010012. 11 pg	IF=1.2	Q3	2019
27	Baseline characteristics of a nationwide cohort of pediatric patients with acute leukemias of Down syndrome.	Sas V, Blag C, Pasca S, Popa G, Marian M, Schnell C, Voda D, Arghirescu ST, Teodorescu P, Iluta S, Turcas C, Selicean C, Bojan A, Zdrengheta M , Serban M, Dima D, Zaharie G, Colita A, Man S, Tomuleasa C.	J BUON.25(6):2737-2746. 10 pg	IF=2.533	Q4	2020
28	TET2 rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis.	Lighezan DL, Bojan AS, Iancu M, Pop RM, Gligor-Popa Ș, Tripon F, Cosma AS, Tomuleasa C, Dima D, Zdrengheta M , Fetica B, Ioniță I, Gaál IO, Vișan S, Miirea AM, Popp RA, Florea M, Aranciu C, Petrescu L, Pop	J Pers Med.;10(4):259. doi: 10.3390/jpm10040259. 16 pg	IF=4.433	Q1	2020


		IV, Bănescu C, Trifa AP.				
29	MicroRNA-155-5p Plays a Critical Role in Transient Leukemia of Down Syndrome by Targeting Tumor Necrosis Factor Receptor Superfamily Members.	Sas V, Pasca S, Jurj A, Pop L, Muramatsu H, Ono H, Dima D, Teodorescu P, Iluta S, Turcas C, Onaciu A, Munteanu R, Zimta AA, Blag C, Popa G, von Gamm EDA, Arghirescu S, Serban M, Man S, Marian M, Petrushev B, Berce C, Colita A, Zdreghea M , Kojima S, Gulei D, Takahashi Y, Tomuleasa C.	Cell Physiol Biochem. 54(5):994-1012. doi: 10.33594/000000283. 19 pg	N/A	N/A	2020
30	Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab.	Tomuleasa C, Iluta S, Pasca S, Roman A, Picu D, Jitaru C, Teodorescu P, Rus I, Bojan A, Dima D, Zdreghea M , Petrushev B.	Int J Hematol. 112(4):597-598. doi: 10.1007/s12185-020-02989-5. Epub 2020 Sep 4. 2 pg	IF=2.49	Q3	2020
31	SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?	Turcas C, Moisoiu V, Stefancu A, Jurj A, Iancu SD, Teodorescu P, Pasca S, Bojan A, Trifa A, Iluta S, Zimta AA, Petrushev B, Zdreghea M , Bumbea H, Coriu D, Dima D, Leopold N, Tomuleasa C.	Front Oncol. 10:1024. doi: 10.3389/fonc.2020.01024. eCollection 2020. 12 pg	IF=6.244	Q2	2020
32	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.	Scarfo L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JA, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM.	Leukemia. 34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. 10 pg	IF=11.528	Q1	2020

12



	<p>Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L, Levin MD, Lista E, Mauro FR, Šimkovič M, Van Der Spek E, Vandenbergh E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrengha M, Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P.</p>			
33	<p>Vitamin D deficiency and the COVID-19 pandemic.</p>	<p>J Glob Antimicrob Resist. Sep;22:133-134. doi: 10.1016/j.jgar.2020.05.006. Epub 2020 May 29. 2 pg</p>	<p>IF=4.035 Q2</p>	<p>2020</p>
34	<p>The Influence of Methylating Mutations on Acute Myeloid Leukemia: Preliminary Analysis on</p>	<p>Diagnosics (Basel). 10(5):263. doi: 10.3390/diagnostics10050263. 12 pg</p>	<p>IF=3.706 Q2</p>	<p>2020</p>

56 Patients.	AA, Sas V, Constantinescu C, Zdrenghia M , Dima D, Tomuleasa C.	Herishanu Y, Shaulov A, Fineman R, Bašić-Kinda S, Aviv A, Wasik-Szczepanek E, Jaksic O, Zdrenghia M , Greenbaum U, Mandac I, Simkovic M, Morawska M, Benjamini O, Spacek M, Nemets A, Bairey O, Trentin L, Ruchlemer R, Laurenti L, Stanca Ciocan O, Doubek M, Shvidel L, Dali N, Mirás F, De Meüter A, Dimou M, Mauro FR, Coscia M, Bumbea H, Szász R, Tadmor T, Gutwein O, Gentile M, Scarfò L, Tedeschi A, Sportoletti P, Gimeno Vázquez E, Marquet J, Assouline S, Papaioannou M, Braester A, Levato L, Gregor M, Rigolin GM, Loscertales J, Medina Perez A, Nijziel MR, Popov VM, Collado R, Slavutsky I, Itchaki G, Ringelstein S, Goldschmidt N, Perry C, Levi S, Polliack A, Ghia P.	Am J Hematol. 95(6):604-611. doi: 10.1002/ajh.25766. 8 pg	IF=10.047	Q1	2020
35	Frontline treatment with the combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.	Pasca S, Jurj A, Zdrenghia M , Tomuleasa C.	Cancers (Basel). 13(7):1499. doi: 10.3390/cancers13071499. 12 pg	IF=6.126	Q1	2021
36	The Potential Equivalents of TET2 Mutations.	Lazar DR, Farcas AD, Blag C, Neaga A, Zdrenghia MT , Cainap C, Lazar FL, Stef A, Cainap SS.	Disease Markers ID 8828410. 9 pg	IF=2.738	Q2	2021
37	Cardiotoxicity: A Major Setback in Childhood Leukemia Treatment	Pasca S, Jurj A, Constantinescu	Crit Rev Immunol.;41(1):13-21.	IF=1.404	Q4	2021
38	Implications of TET2 in					



	CAR-T Cell Activity and Target Response to CAR-T Cell Therapy: Lessons Learned from T Cells.	C. Zdrenghea M, Tomuleasa C.	doi:10.1615/CritRevImmunol.2020036946. 9 pg		
39	Azaeytidine plus olaparib for relapsed acute myeloid leukaemia, ineligible for intensive chemotherapy, diagnosed with a synchronous malignancy	Iluta S, Pasca S, Gafencu G, Jurj A, Terec A, Teodorescu P, Selicean C, Jitaru C, Preda A, Cenariu D, Constantinescu C, Iordache M, Tigu B, Munteanu R, Feder R, Dima D, Zdrenghea M, Gulei D, Ciuleanu TE, Tomuleasa C	JOURNAL OF CELLULAR AND MOLECULAR MEDICINE doi.org/10.1111/jcmm.16513 9 pg	IF=5.31	Q2 2021

¹ se va nota (prim autor, autor corespondent, ultim autor, autor cu contributii egale)

² se va nota, factorul de impact in anul aparitiei articolului

³ se va nota anul aparitiei articolului

2. Articole publicate in extenso in reviste si volumele unor manifestari stiintifice indexate BDI

Autor principal

Nr. Crt.	Titlul	Autorii	Calitatea autorului ¹	Revista, volum, nr. pagini	Anul ²
1	Leukemic and cryptococcal meningitis in an alemtuzumab-treated chronic lymphocytic leukemia patient - a case report.	Popescu C, Urian L, Patiu M, Flonta M, Bagacean C, Radeanu D, Petrov L, Zdrenghea M.	Ultim autor	HVM Bioflux:7(4):294-297. 4 pg	2015
2	Diffuse large B-cell lymphoma response to Rituximab-PMitCEBO regimen is not predicted by FcγRIIIa158 polymorphism.	Bagacean C, Lombion N, Tempescul A, Ianotto JC, Berthou C, Renaudineau Y, Zdrenghea M, Cristea V.	Autor corespondent	HVM Bioflux:7(4):298-301. 4 pg	2015
3	CD20 negative relapse of a follicular lymphoma after chemoimmunotherapy.	Bagacean C, Quintin-Roue I, Ianotto JC, Renaudineau Y, Tempescul A, Radeanu D, Muresan A, Zdrenghea M.	Ultim autor	HVM Bioflux:7(4):302-305 4 pg	2015

¹ se va nota (prim autor, autor corespondent, ultim autor, autor cu contributii egale)

² se va nota anul aparitiei articolului

Coautor

Nr. Crt.	Titlul	Autorii	Revista, volum, nr. pagini	Anul ²
1	Arterial stenosis and atherothrombotic events in polycythemia vera and essential thrombocythemia.	Cucuianu A, Stoia M, Farcas A, Dima D, Zdrenghea M, Patiu M, et al.	Rom J Intern Med.;44(4):397-406 9 pg	2006
2	DNA demethylation marks in chronic lymphocytic leukemia: it is time to let the cat out of the bag.	Bagacean C, Zdrenghea M, Dantec CL, Temescul A, Berthou C, Renaudineau Y.	Future Sci OA. 2017 Nov3;4(2):FSO265. doi:10.4155/fsoa-2017-0120.	2017

² se va nota anul aparitiei articolului

3. Alte articole

Nr. Crt.	Titlul	Autorii	Calitatea autorului ¹	Revista, volum, nr. pagini	Anul ²


¹ se va nota (prim autor, autor corespondent, ultim autor, autor cu contributii egale, coautor)

² se va nota anul aparitiei articolului


4. Articole ISI (Web of Science, Core collection) in extenso de la ultima promovare

Nr. Crt.	Titlul	Autorii	Calitatea autorului ¹	Revista, volum, nr. pagini	Factorul de impact ²	Quartila	Anul ³
1	Vitamin D increases the antiviral activity of bronchial epithelial cells in vitro.	Telcian, AG; Zdrenghea, MT; Edwards, MR; Laza-Stanca, V; Mallia, P; Johnston, SL; Stanciu, LA.	Autor corespondent	ANTIVIRAL RESEARCH;137:93-101 .doi:10.1016/j.antiviral.2016.11.004 8 pg	IF=4.3	Q1	2017
2	Atypical aleukemic presentation of large granular lymphocytic leukemia: a case report.	Bagacean, C; Temescul, A; Patiu, M; Fetica, B; Bumbea, H; Zdrenghea, M.	Ultim autor	ONCOTARGETS AND THERAPY;10:31-34 .doi:10.2147/OTT.S115892 4 pg	IF=2.65	Q3	2017


16




3	The use of rotation to fentanyl in cancer-related pain.	Dima, D; Tomuleasa, C; Frinc, I; Pasca, S; Magdo, L; Berindan-Neagoe, I; Muresan, M; Lisencu, C; Irimie, A; Zdrenghea, M.	Ultim autor	JOURNAL OF PAIN RESEARCH;10:341-348 .doi:10.2147/JPR.S121920 7 pg	IF=2.64	Q3	2017
4	Vitamin D modulation of innate immune responses to respiratory viral infections.	Zdrenghea, MT ; Makrinioti, H; Bagacean, C; Bush, A; Johnston, SL; Stanciu, LA.	Prim autor	REVIEWS IN MEDICAL VIROLOGY;271:-e1909.doi:10.1002/rmv.1909	IF=5.034	Q1	2017
5	Immune checkpoint blockade: the role of PD-1-PD-L axis in lymphoid malignancies.	Ilcus, C; Bagacean, C; Tempescul, A; Popescu, C; Parvu, A; Cenariu, M; Bocsan, C; Zdrenghea, M.	Ultim autor	ONCOTARGETS AND THERAPY;10:2349-2363 .doi:10.2147/OTT.S133385 14 pg	IF=2.65	Q3	2017
6	Xanthine oxidase inhibitors in ischaemic heart disease.	Zdrenghea, M ; Sitar-Taut, A; Cismaru, G; Zdrenghea, D; Pop, D	Prim autor	CARDIOVASCULAR JOURNAL OF AFRICA;283:201-204 .doi:10.5830/CVJA-2016-068 4 pg	IF=1.12	Q4	2017
7	Chondroprotective effects of pulsed shortwave therapy in rabbits with experimental osteoarthritis.	Ungur, RA; Florea, A; Tabaran, AF; Scurtu, IC; Onac, I; Borda, IM; Irsay, L; Ciortea, VM; Dronca, E; Zdrenghea, MT ; Suci, SM.	Coautor	ROMANIAN JOURNAL OF MORPHOLOGY AND EMBRYOLOGY;582:465-472 7 pg	IF=0.912	Q4	2017
8	Combining cytogenetic and epigenetic approaches in chronic	Bagacean C, Le Dantec C, Berthou C, Tempescul A, Saad H, Bordron A, Zdrenghea M , Cristea V, Douet-Guilbert N, Renaudineau Y.	Coautor	Clin Epigenetics.;9:122. doi: 10.1186/s13148-017-0422-7.	IF=6.091		2017




	lymphocytic leukemia improves prognosis prediction for patients with isolated 13q deletion.						
9	Echocardiography as the first diagnostic clue to rapidly progressive systemic AL amyloidosis associated with multiple site thrombosis. A case report.	Caloian B, Zdrenghia D, Man SC, Costea S, Zdrenghia M , Pop D.	Coautor	Med Ultrasoun.:19(4):451-453. doi: 10.11152/mu-1095. 3 pg	IF=1.512	Q3	2017
10	Adult acute megakaryoblastic leukemia: rare association with cytopenias of undetermined significance and p210 and p190 BCR-ABL transcripts.	Dima D, Oprita L, Rosu AM, Trifa A, Selicean C, Moisoiu V, Frinc I, Zdrenghia M , Tomuleasa C.	Coautor	Onco Targets Ther. 10:5047-5051. doi: 10.2147/OTT.S14697 3. 5 pg	IF=2.65	Q3	2017
11	NT-PRO-BNP AND URIC ACID LEVELS CORRELATE IN PATIENTS WITH COPD AND HEART	Iosip, A; Pop, D; Sitar-Taut, A; Niculescu, I; Calotian, B; Zdrenghia D ; Zdrenghia M	Ultim autor	ACTA MEDICA MEDITERRANEA;34 1:189-195 .doi:10.19193/0393-6384_2018_1_31 6 pg	IF=0.35	Q3	2018




12	FAILURE. Preserved lenalidomide efficacy in a recurrent isolated subcutaneous mantle cell lymphoma relapse.	Bagacean C, Neaga A, Zdrenghea M, Tempeşcul A.	Autor corespondent	J BUON.;23(1):273-274. 2 pg	IF=1.379	Q4	2018
13	Modest contribution of JAK2 V617F allele burden to the occurrence of major thrombosis in polycythemia vera and essential thrombocythemia.	Trifa AP, Bănescu C, Voina CM, Popa Ş, Török-Vistai T, Bojan AS, Dima D, Zdrenghea M, Fetica B, Vişan S, Tomuleasa C, Pârvu A, Urian L, Pop B, Popov VM, Andreescu M, Popp RA.	Coautor	BLOOD CELLS MOLECULES AND DISEASES. 73: 45-46 2 pg	IF=2.305	Q3	2018
14	Exosome-carried microRNA-based signature as a cellular trigger for the evolution of chronic lymphocytic leukemia into Richter syndrome.	Jurj A, Pop L, Petrushev B, Pasca S, Dima D, Frinc I, Deak D, Desmirean M, Trifa A, Fetica B, Gafencu G, Selicean S, Moisoiu V, Micu WT, Berce C, Sacu A, Moldovan A, Colita A, Bumbea H, Tanase A, Dascalescu A, Zdrenghea M, Stiuftuc R, Leopold N, Tetean R, Burzo E, Tomuleasa C, Berindan-Neagoe I.	Coautor	Crit Rev Clin Lab Sci. ;55(7):501-515. doi: 10.1080/10408363.2018.1499707 15 pg	IF=4.817	Q1	2018
15	Minimal residual disease in chronic lymphocytic leukemia: A consensus paper that presents the clinical impact of the presently	Tomuleasa C, Selicean C, Cismas S, Jurj A, Marian M, Dima D, Pasca S, Petrushev B, Moisoiu V, Micu WT, Vischer A, Arifeen K, Selicean S, Zdrenghea M, Bumbea H, Tanase A, Grewal R, Pop L, Aanei C, Berindan-Neagoe I.	Coautor	Crit Rev Clin Lab Sci. 55(5):329-345. doi: 10.1080/10408363.2018.1463508. Epub 2018 May 25.	IF=4.817	Q1	2018



16	available laboratory approaches.	Fibroblast dynamics as an in vitro screening platform for anti-fibrotic drugs in primary myelofibrosis.	Tomuleasa, C; Selicean, S; Gafencu, G; Petrushev, B; Pop, L; Berce, C; Jurj, A; Trifa, A; Rosu, AM; Pasca, S; Magdo, L; Zdrenghea, M; Dima, D; Tanase, A; Frinc, I; Bojan, A; Berindan-Neagoe, I; Ghiaur, G; Ciurea, SO.	Coautor	JOURNAL OF CELLULAR PHYSIOLOGY;2331:422-433 .doi:10.1002/jcp.25902 12 pg	IF=4.522	Q2	2018
17	A Review of Macrophage MicroRNAs' Role in Human Asthma.	Feketea G, Bocsan CI, Popescu C, Gaman M, Stanciu L.A. Zdrenghea MT.	Ultim autor		Cells.;8(5):420. doi: 10.3390/cells8050420 21 pg	IF=4.366	Q2	2019
18	Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients?	Popescu CM, Ursache AL, Feketea G, Bocsan C, Jimbu L, Mesaros O, Edwards M, Wang H, Berceanu I, Neaga A. Zdrenghea M.	Ultim autor		Microorganisms.;7(11):521. doi: 10.3390/microorganisms7110521. 23 pg	IF=4.128	Q2	2019
19	Rapid and complete response to idelalisib in a case of Richter syndrome.	Bagacean C, Zdrenghea M , Saad H, Berthou C, Renaudineau Y, Tempescul A.	Coautor		Onco Targets Ther.;12:1181-1184. doi: 10.2147/OTT.S187459 4 pg	IF=3.046	Q2	2019
20	17p deletion strongly influences rituximab elimination in chronic lymphocytic leukemia.	Bagacean C, Tempescul A, Ternant D, Banet A, Douet-Guilbert N, Bordron A, Bendaoud B, Saad H. Zdrenghea M , Berthou C, Paintaud G, Renaudineau Y.	Coautor		J Immunother Cancer.;7(1):22. doi: 10.1186/s40425-019-0509-0.	IF=10.252	Q1	2019




21	Approach to the Adult Acute Lymphoblastic Leukemia Patient.	Sas V, Moisoiu V, Teodorescu P, Tranca S, Pop L, Iluta S, Pasca S, Blag C, Man S, Roman A, Constantinescu C, Rus I, Buse M, Fetica B, Marian M, Selicean C, Berindan-Neagoe I, Petrushev B, Bumbea H, Tanase A, Zdrengha M, Fuji S, Kitano S, Tomuleasa C; Romanian-Japanese Working Group of the Romanian Society for Bone Marrow Transplantation.	Coautor	J Clin Med.;8(8):1175. doi: 10.3390/jcm8081175.	IF_3.303	Q1	2019
22	Transient leukemia of Down syndrome.	Sas V, Blag C, Zaharie G, Puscas E, Lisencu C, Andronic-Gorcea N, Pasca S, Petrushev B, Chis I, Marian M, Dima D, Teodorescu P, Iluta S, Zdrengha M , Berindan-Neagoe I, Popa G, Man S, Colita A, Stefan C, Kojima S, Tomuleasa C.	Coautor	Crit Rev Clin Lab Sci.;56(4):247-259. doi:10.1080/10408363.2019.1613629. 13 pg	IF=4.677	Q1	2019
23	Assessing Measurable Residual Disease in Chronic Myeloid Leukemia. BCR-ABL1 IS in the Avant-Garde of Molecular Hematology.	Moisoiu V, Teodorescu P, Parajdi L, Pasca S, Zdrengha M , Dima D, Precup R, Tomuleasa C, Soverini S.	Coautor	Front Oncol. 9:863. doi: 10.3389/fonc.2019.00863. 8 pg	IF=4.848	Q2	2019
24	Persistent Basophilia May Suggest an "Accelerated Phase" in the Evolution of CALR-Positive	Dobrowolski J, Pasca S, Teodorescu P, Selicean C, Rus I, Zdrengha M , Bojan A, Trifa A, Fetica B, Petrushev B, Rosu AM, Berindan-Neagoe I, Tomuleasa C, Dima D.	Coautor	Front Oncol. 9:872. doi: 10.3389/fonc.2019.00872. 7 pg	IF=4.848	Q2	2019




25	Primary Myelofibrosis Toward Acute Myeloid Leukemia. CV RISK - A new relative cardiovascular risk score.	Zdrengheta D, Guşetu G, Zdrengheta M , Cismaru G, Caloian B, Vaidean G, Pop D.	Coautor	Med Hypotheses. 132:109362. doi: 10.1016/j.mehy.2019.109362. 4 pg	IF=1.378	Q4	2019
26	Let's Talk About BITEs and Other Drugs in the Real-Life Setting for B-Cell Acute Lymphoblastic Leukemia.	Deak D, Pop C, Zimta AA, Jurj A, Ghiaur A, Pasca S, Teodorescu P, Dascalescu A, Antohe I, Ionescu B, Constantinescu C, Onaciu A, Munteanu R, Berindan-Neagoe I, Petrushev B, Turcas C, Iluta S, Selicean C, Zdrengheta M , Tanase A, Danaila C, Colita A, Colita A, Dima D, Coriu D, Einsele H, Tomuleasa C.	Coautor	Front Immunol.10:2856. doi: 10.3389/fimmu.2019.02856. 16 pg	IF=7.561	Q1	2019
27	Splenectomy in Lymphoproliferative Disorders: A Single Eastern European Center Experience.	Onisai M, Vlădăreanu AM, Nica A, Spînu A, Găman M, Bumbea H, Voican I, Iordan I, Alexandru A, Zdrengheta M , Gheorghita D, Grădinaru S.	Coautor	Medicina (Kaunas). 56(1):12. doi: 10.3390/medicina56010012. 11 pg	IF=1.2	Q3	2019
28	The Role of Vitamin D Deficiency in Children With Recurrent Wheezing-Clinical Significance.	Feketea G, Boesan CI, Stanciu LA, Buzoianu AD, Zdrengheta MT .	Ultim autor	Front Pediatr.;8:344. doi: 10.3389/fped.2020.00344. eCollection 2020 7 pg	IF=3.418	Q1	2020
29	Macrophage Polarization in Chronic	Mesaros O, Jimbu L, Neaga A, Popescu C, Berceanu I, Tomuleasa C, Fetica B, Zdrengheta M .	Ultim autor	Biomedicines.8(11):516. doi: 10.3390/biomedicines	IF=6.081	Q1	2020


	Lymphocytic Leukemia: Nurse-Like Cells Are the Caretakers of Leukemic Cells.			8110516 17 pg			
30	TET2/IDH1/2/WT1 and NPM1 Mutations Influence the RUNX1 Expression Correlations in Acute Myeloid Leukemia.	Pasca, S; Jurj, A; Tomuleasa, C; Zdrenghea, M.	Ultim autor	MEDICINA-LITHUANIA 5; 612:-637.doi:10.3390/medicina56120637	IF=2.43	Q2	2020
31	Baseline characteristics of a nationwide cohort of pediatric patients with acute leukemias of Down syndrome.	Sas V, Blag C, Pasca S, Popa G, Marian M, Schnell C, Voda D, Arghirescu ST, Teodorescu P, Iluta S, Turcas C, Selicean C, Bojan A, Zdrenghea M , Serban M, Dima D, Zaharie G, Colita A, Man S, Tomuleasa C.	Coautor	J BUON.25(6):2737-2746. 10 pg	IF=2.533	Q4	2020
32	TET2 rs1548483 SNP Associating with Susceptibility to Molecularly Annotated Polycythemia Vera and Primary Myelofibrosis.	Lighezan DL, Bojan AS, Iancu M, Pop RM, Gligor-Popa S, Tripon F, Cosma AS, Tomuleasa C, Dima D. Zdrenghea M , Fetica B, Ionita I, Gaal IO, Visan S, Mirea AM, Popp RA, Florea M, Aranicu C, Petrescu L, Pop IV. Bănescu C, Trifa AP.	Coautor	J Pers Med.:10(4):259. doi: 10.3390/jpm10040259 . 16 pg	IF=4.433	Q1	2020
33	MicroRNA-155-5p Plays a Critical Role in Transient Leukemia of Down	Sas V, Pasca S, Jurj A, Pop L, Muramatsu H, Ono H, Dima D, Teodorescu P, Iluta S, Turcas C, Onaciu A, Munteanu R, Zimta AA.	Coautor	Cell Physiol Biochem. 54(5):994-1012. doi: 10.33594/00000283. 19 pg	N/A	N/A	2020




	Syndrome by Targeting Tumor Necrosis Factor Receptor Superfamily Members.	Blag C, Popa G, von Gamm EDA, Arghirescu S, Serban M, Man S, Marian M, Petrushev B, Berce C, Colita A, Zdrengha M , Kojima S, Gulei D, Takahashi Y, Tomuleasa C.					
34	Complete metabolic remission in an 84-year old patient with relapsed/refractory diffuse large B-cell lymphoma following combination immunotherapy with lenalidomide plus rituximab.	Tomuleasa C, Iluta S, Pasca S, Roman A, Piciu D, Jitaru C, Teodorescu P, Rus I, Bojan A, Dima D, Zdrengha M , Petrushev B.	Coautor	Int J Hematol.112(4):597-598. doi: 10.1007/s12185-020-02989-5. Epub 2020 Sep 4. 2 pg	IF=2.49	Q3	2020
35	SERS-Based Assessment of MRD in Acute Promyelocytic Leukemia?	Turcas C, Moisoiu V, Stefancu A, Jurj A, Iancu SD, Teodorescu P, Pasca S, Bojan A, Trifa A, Iluta S, Zimta AA, Petrushev B, Zdrengha M , Bumbea H, Coriu D, Dima D, Leopold N, Tomuleasa C.	Coautor	Front Oncol. 10:1024. doi: 10.3389/fonc.2020.01024. eCollection 2020. 12 pg	IF=6.244	Q2	2020
36	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.	Scarfò L, Chatzikonstantinou T, Rigolin GM, Quaresmini G, Motta M, Vitale C, Garcia-Marco JA, Hernández-Rivas JA, Mirás F, Baile M, Marquet J, Niemann CU, Reda G, Munir T, Gimeno E, Marchetti M, Quaglia FM, Varettoni M, Delgado J, Iyengar S, Janssens A, Marasca R, Ferrari A, Cuéllar-García C, Itchaki G, Špaček M, De Paoli L, Laurenti L,	Coautor	Leukemia. 34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. 10 pg	IF=11.528	Q1	2020



37	Vitamin D deficiency and the COVID-19 pandemic.	Levin MD, Lista E, Mauro FR, Šimković M, Van Der Spek E, Vandenberghe E, Trentin L, Wasik-Szczepanek E, Ruchlemer R, Bron D, De Paolis MR, Del Poeta G, Farina L, Foglietta M, Gentile M, Herishanu Y, Herold T, Jaksic O, Kater AP, Kersting S, Malerba L, Orsucci L, Popov VM, Sportoletti P, Yassin M, Pocali B, Barna G, Chiarenza A, Dos Santos G, Nikitin E, Andres M, Dimou M, Doubek M, Enrico A, Hakobyan Y, Kalashnikova O, Ortiz Pareja M, Papaioannou M, Rossi D, Shah N, Shrestha A, Stanca O, Stavroyianni N, Strugov V, Tam C, Zdrenghea M , Coscia M, Stamatopoulos K, Rossi G, Rambaldi A, Montserrat E, Foà R, Cuneo A, Ghia P.	Coautor	J Glob Antimicrob Resist. Sep;22:133-134. doi: 10.1016/j.jgar.2020.05.006. Epub 2020 May 29. 2 pg	IF=4.035	Q2	2020
38	The Influence of Methylating Mutations on Acute Myeloid Leukemia: Preliminary Analysis on 56 Patients.	Zemb P, Bergman P, Camargo CA Jr, Cavalier E, Cormier C, Courbebaïsse M, Hollis B, Joulia F, Minisola S, Pilz S, Pludowski P, Schmitt F, Zdrenghea M , Souberbielle JC.	Coautor	Diagnosics (Basel). 10(5):263. doi: 10.3390/diagnostics10050263. 12 pg	IF=3.706	Q2	2020
39	Frontline treatment with the	Herishanu Y, Shaulov A, Fineman R, Bašić-Kinda S, Aviv A, Wasik-	Coautor	Am J Hematol. 95(6):604-611. doi:	IF=10.047	Q1	2020



	combination obinutuzumab ± chlorambucil for chronic lymphocytic leukemia outside clinical trials: Results of a multinational, multicenter study by ERIC and the Israeli CLL study group.	Szcepanek E, Jaksic O, Zdrengha M , Greenbaum U, Mandac I, Simkovic M, Morawska M, Benjamini O, Spacek M, Nemets A, Bairey O, Trentin L, Ruchlemer R, Laurenti L, Stanca Ciocan O, Doubek M, Shvidel L, Dali N, Mirás F, De Meuter A, Dimou M, Mauro FR, Coscia M, Bumbea H, Szász R, Tadmor T, Gutwein O, Gentile M, Scarfo L, Tedeschi A, Sportoletti P, Gimeno Vázquez E, Marquet J, Assouline S, Papaioannou M, Braester A, Levato L, Gregor M, Rigolin GM, Loscertales J, Medina Perez A, Nijziel MR, Popov VM, Collado R, Slavutsky I, Itchaki G, Ringelstein S, Goldschmidt N, Perry C, Levi S, Polliack A, Ghia P.	10.1002/ajh.25766. 8 pg		
40	MicroRNAs Associated With a Good Prognosis of Acute Myeloid Leukemia and Their Effect on Macrophage Polarization.	Neaga A, Bageacan C, Tempescul A, Jimbu L, Mesaros O, Blag C, Tomuleasa C, Bocsan C, Gaman M, Zdrengha M .	Front Immunol.11:582915. doi: 10.3389/fimmu.2020.582915 14 pg	IF=5.085 Q1	2021
41	Vitamin D Status in Children in Greece and Its Relationship with Sunscreen Application.	Feketea GM, Bocsan IC, Tsiros G, Voila P, Stanciu LA, Zdrengha M .	Children (Basel). 8(2):111. doi: 10.3390/children802111. 11 pg	IF=2.078 Q2	2021
42	Vitamin D in Corona Virus Disease 2019 (COVID-19)	Feketea G, Vlacha V, Bocsan IC, Vassilopoulou E, Stanciu LA, Zdrengha M .	Front Immunol. 12:648546. doi:10.3389/fimmu.2021.648546	IF=5.085 Q1	2021



	Related Multisystem Inflammatory Syndrome in Children (MIS-C).				7 pg				
43	Is There a Place for PD-1-PD-L Blockade in Acute Myeloid Leukemia?	Jimbu L, Mesaros O, Popescu C, Neaga A, Berceanu I, Dima D, Gaman M, Zdrenghea M.	Ultim autor	Pharmaceuticals (Basel). 14(4):288. doi:10.3390/ph14040288 18 pg	IP=4,286	Q1		2021	
44	The Potential Equivalents of TET2 Mutations.	Pasca S, Jurj A, Zdrenghea M, Tomuleasa C.	Coautor	Cancers (Basel). 13(7):1499. doi:10.3390/cancers13071499. 12 pg	IP=6,126	Q1		2021	
45	Cardiotoxicity: A Major Setback in Childhood Leukemia Treatment	Lazar DR, Farcas AD, Blag C, Neaga A, Zdrenghea MT, Cainap C, Lazar FL, Stef A, Cainap SS.	Coautor	Disease Markers ID 8828410. 9 pg	IP=2,738	Q2		2021	
46	Implications of TET2 in CAR-T Cell Activity and Target Response to CAR-T Cell Therapy: Lessons Learned from T Cells.	Pasca S, Jurj A, Constantinescu C, Zdrenghea M, Tomuleasa C.	Coautor	Crit Rev Immunol;41(1):13-21. doi:10.1615/CritRevImmunol.2020036946. 9 pg	IP=1,404	Q4		2021	
47	Azacytidine plus olaparib for relapsed acute myeloid leukaemia. ineligible for	Iluta S, Pasca S, Gafencu G, Jurj A, Terec A, Teodorescu P, Selicean C, Jitaru C, Preda A, Cenariu D, Constantinescu C, Iordache M, Tigiu B, Munteanu R, Feder R, Dima D.	Coautor	JOURNAL OF CELLULAR AND MOLECULAR MEDICINE doi.org/10.1111/jcmm.	IP=5,31	Q2		2021	

intensive chemotherapy, diagnosed with a synchronous malignancy	Zdrenghea M, Gulei D, Ciuleanu TE, Tomuleasa C	16513 9 pg		
---	--	---------------	--	--

¹ se va nota *(prim autor, autor corespondent, ultim autor, autor cu contribuții egale, coautor)*

² se va nota *factorul de impact în anul apariției articolului*

³ se va nota *anul apariției articolului*

5. Articole BDI in extenso de la ultima promovare

Nr. Crt.	Titlul	Autorii	Calitatea autorului ¹	Revista, volum, nr. pagini	Anul ²
1	DNA demethylation marks in chronic lymphocytic leukemia: it is time to let the cat out of the bag.	Bagacean C, Zdrenghea M, Dantec CL, Tempescul A, Berthou C, Renaudineau Y.	coautor	Future Sci OA. 2017 Nov3;4(2):FSO265. doi:10.4155/fsoa-2017-0120.	2017

¹ se va nota *(prim autor, autor corespondent, ultim autor, autor cu contribuții egale, coautorii)*

² se va nota *anul apariției articolului*

IMPORTANT:

A. Cauze de invalidare a unei lucrări publicate în extenso:
Date incomplete de identificare

B. Modalitatea de prezentare a activității științifice:


Numerotarea lucrărilor se va face în ordinea progresivă a zilei, lunii și a anului publicării

C. Excluderea din concurs:

Plagiatul dovedit

Identificarea unei lucrări ca publicație duală CU EXCEPȚIA celor publicate în reviste de limbi diferite: ex. română - franceză sau română - engleză etc.

Identificarea dublării unei lucrări publicate în rezumat și apoi în extenso, incluse de candidat ca două lucrări separate.



Lista cărților publicate

Cărți și capitole în edituri internaționale de prestigiu

Nr. crt.	TITLUL lucrării / capitolului/	Calitatea	Carte/capitol	Nr. pag.	Editura	Localitatea	Anul
1.	Antiinflammatory, immunomodulatory and antiallergic effects of <i>Nigella sativa</i> .	autor	capitol	45	Nova Science Publisher	New York, USA	2018

Cărți și capitole în edituri internaționale + românești

Nr. crt.	TITLUL lucrării / capitolului/	Calitatea	Carte/capitol	Nr. pag.	Editura	Localitatea	Anul
1	New approaches to the management of primary and secondary CNS tumors	Autor	Capitol	19	Intech	Rijeka	2017

Cărți și capitole edituri de top din România

Nr. crt.	TITLUL	Calitatea	Carte/capitol	Nr. pag.	editura	Localitatea	Anul
1	Manual of clinical hematology ISBN 978-973-133-279-6	Coautor	Carte	151	Casa Cărții de Știință	Cluj Napoca	2008
2	Manual of clinical hematology. ISBN 978-973-133-998-6	Coautor	Carte	172	Casa Cărții de Știință	Cluj Napoca	2011
3	Manual of clinical hematology. (coautor) ISBN 978-973-133-998-6	Coautor	Carte	172	Casa Cărții de Știință	Cluj Napoca	2012
4	Protocoale de diagnostic si	Coautor	Carte	182 pag	Casa Cărții de	Cluj Napoca	2014

	tratament in hematologie. ISBN 978-606-17-0496-5				Știință		
5	Neoplasmele tesutului limfoid: limfoamele. ISBN 978-606-17-0726-3.	Autor	Carte	94 pag	Casa Cărții de Știință	Cluj Napoca	2015
6	Neoplasmele mieloproliferative – autor coordonator carte/ 124 pagini ISBN 978-606-17-1135-1	Autor	Carte	124 pg	Casa Cărții de Știință	Cluj Napoca	2017

Cărți și capitole alte edituri cu ISBN

Nr. crt.	TITLUL	Calitatea	Carte/capitol	nr. pag.	editura	Localitatea	Anul
1	Nanopharmacology in leukemia chemotherapy	Coautor	capitol	41 pg	Eikon	Cluj Napoca	2015
2	Chimioterapie hematologică ISBN 978-606-8770-30-7	Autor	carte	211 pg	Eikon	Cluj Napoca	2016
3	Transplantul medular în limfoamele Hodgkin	Autor	capitol	12 pg	Eikon	Cluj Napoca	2017
4	Leucemia meloidă cronică. De la terapia cu inhibitori de tirozin kinazăe la transplant ISBN 978-606-8770-98-7	Coautor	carte	155 pag	Eikon	Cluj Napoca	2017

Carti sau cursuri publicate cu destinatie universitara:

Nr. crt.	TITLUL lucrarii / capitolului/ nr. pag.	sub redactia: / titlul	editura	Localitatea	Anul	Nr. pag

Carti sau cursuri publicate cu destinatie postuniversitara:

Nr. crt.	TITLUL lucrarii / capitolului/ nr. pag.	sub redactia: / titlul	Editura	Localitatea	Anul	Nr. pag

FACULTATEA DE MEDICINĂ

Fișa de verificare a îndeplinirii standardelor minime naționale și specifice universității pentru examenul de promovare în cariera didactică pentru postul de PROFESOR UNIVERSITAR

Departamentul nr. 11 Oncologie - Disciplina Hematologie

Post: **Profesor universitar**, poziția 6

Candidat: **Zdrenghea Mihnea**

1. Medic primar NU ESTE CAZUL DA NU
2. Doctor în științe DA NU
3. Atestat de abilitare DA NU
4. Evaluare colegială și a șefului de disciplină, conform normelor în vigoare DA NU
5. În ultimii 3 ani a obținut calificativul „foarte bine” și nu a fost sancționat disciplinar DA NU
6. Vechimea minimă de 9 ani în calitate de cadru didactic titular DA NU
7. Date privind îndeplinirea standardelor minime naționale și specifice UMF „Iuliu Hațieganu”

Criterii de promovare	Profesor		
	Criterii minime	Gradul de îndeplinire	
		DA	NU
Standarde minime naționale			
Articole *ISI ca autor principal	10	X	
Articole *ISI coautor	5	X	
Index HIRSCH – calculat pe ISI Web of Science, Core collection	6	X	
Factor cumulativ de impact autor principal (FCIAP)	10	X	
Standardelor specifice UMF „Iuliu Hațieganu”			
Cărți de specialitate (autor sau coordonator), din care una de la ultima promovare	2	X	
SAU			
Capitole în tratate naționale (prim autor sau coautor cu contribuții egale), din care 3 de la ultima promovare	6	X	
SAU			
Capitole în edituri internaționale (prim autor sau coautor cu contribuții egale), din care 2 de la ultima promovare	3		
Articole în extenso din domeniul postului, publicate în reviste științifice indexate ISI sau BDI, din care 5 de la ultima promovare	25	X	

În analiză vor fi incluse articole originale și reviews. În cazul publicațiilor în reviste cu factor de impact mai mare decât 3, pot fi luate în considerare și alte tipuri de publicații în extenso (nu rezumate)

Comisia de avizare certifică faptul că **SUNT** / **NU SUNT** îndeplinite toate cerințele minime necesare pentru înscrierea candidatului evaluat la concursul pentru ocuparea postului de profesor universitar.

Comisia de avizare

1. Prof. dr. Șoimița Suciu
 2. Prof. dr. Simona Clichici
 3. Prof. dr. Monica Popa



4. Conf. dr. Anca Bojan
 5. Conf. dr. Sorin Crișan
 6. Conf. dr. Blendea Dan



Data: